A Study of LM-350 in Subjects With Advanced Solid Tumours

NCT ID: NCT07112222

Last Updated: 2026-01-26

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-28
• Study Completion Date: 2030-06-30

Brief Summary

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350.

For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.

Conditions

Malignant Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Phase I Dose Escalation Part and Dose Confirmation Part

Group Type: EXPERIMENTAL

LM-350 for injection

Intervention Type: DRUG

Q3W,Intravenous Drip

Interventions

LM-350 for injection

Q3W,Intravenous Drip

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.

2. Participant must be ≥18 years or the legal age of consent at the time of signing the ICF.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

4. Life expectancy ≥ 3 months.

5. Patients with advanced solid tumors confirmed by histopathological diagnosis who have failed standard treatment, are intolerant to standard treatment, or for whom standard treatment is currently unsuitable.

6. Pre-treatment archived tumour tissue (within 3 years) or on-treatment tumour biopsy could be provided for biomarker analysis.

7. Must have at least one measurable lesion according to RECIST v1.1.

8. Adequate organ and bone marrow function as defined by protocol.

9. Subjects who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion Criteria

1. Participate in any other clinical trial within 28 days prior to 1st dosing of LM-350.

2. Subjects who have received treatment with the same targeting.

3. History of ≥ Grade 3 late diarrhea during or after previous treatment with a topoisomerase inhibitor.

4. Subjects who have received the following anti-tumor treatments within the specified time periods prior to the first dosing of LM-350.

5. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.

6. Subjects with uncontrolled tumour-related pain.

7. Subjects with known central nervous system (CNS) or meningeal metastasis.

8. Subjects who have clinically uncontrollable third-space fluid accumulation.

9. Subjects who experienced grade 3 or higher hypersensitivity to the treatment that contains monoclonal antibody.

10. Subjects who take systemic corticosteroids (≥ 10 mg/day of prednisone or equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dose of LM-350.

11. Has a history of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.

12. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, and any autoimmune, or prior pneumonectomy.

13. Use of any live attenuated vaccines within 28 days prior to 1st dosing of LM-350.

14. Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for > 2 weeks prior to the first dose of LM-350.

15. Subjects with active or a documented history of chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease).

16. Subjects with complete or incomplete intestinal obstruction within 3 months prior to the first dose of the study drug , orpatients who are currently at the risk of intestinal perforation.

17. Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-350.

18. Subjects who have severe cardiovascular disease.

19. Subjects who have uncontrolled or severe illness.

20. Subjects who have a history of immunodeficiency disease.

21. HIV infection, active infection including tuberculosis, HBV and HCV infection.

22. Subjects who have other active malignancies which are likely to require the treatment.

23. Child-bearing potential female who have positive results in pregnancy test or are lactating.

24. Subjects who have psychiatric illness or disorders that may preclude study compliance.

25. Subject who is judged as not eligible to participate in this study by the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LaNova Medicines Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Cancer Care Wollongong Pty Limited

Wollongong, New South Wales, Australia

Site Status: RECRUITING

Cancer Research SA

Adelaide, South Australia, Australia

Site Status: RECRUITING

Peninsula and South Eastern Haematology and Oncology Group

Frankston, Victoria, Australia

Site Status: RECRUITING

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Site Status: NOT_YET_RECRUITING

Countries

Australia; China

Central Contacts

Alex Yuan

Role: CONTACT

alexyuan@lanovamed.com

+8615901815211

Facility Contacts

Udit Nindra

Role: primary

Vineet kwatra

Role: primary

Dr Vinod Ganju

Role: primary

Lin Shen

Role: primary

Other Identifiers

LM350-01-101

Identifier Type: -

Identifier Source: org_study_id